CV Therapeutics, Inc. is a biopharmaceutical company headquartered in Palo Alto, CA. Focused on the development of novel small molecule therapeutics for the treatment of cardiovascular diseases, CV Therapeutics has emerged as a leader in cardiovascular medicine. In April 2009, CV Therapeutics was acquired by Gilead Sciences, Inc.
There is no investment information
No recent news or press coverage available for CV Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
